Abstract | SCOPE: METHOD AND RESULTS: Fischer 344 rats are fed a choline-deficient l- amino acid-defined ( CDAA) diet for 12 weeks and treated with oral losartan (30 mg kg-1 day-1 ) and/or BCAAs (Aminoleban EN, 2500 mg kg-1 day-1 ). Treatment with losartan and BCAAs attenuated hepatic inflammation and fibrosis and improved skeletal muscle atrophy and strength in CDAA-fed rats. Both agents reduced intramuscular myostatin and pro-inflammatory cytokine levels, resulting in inhibition of the ubiquitin- proteasome system (UPS) through interference with the SMAD and nuclear factor-kappa B pathways, respectively. Losartan also augmented the BCAA-mediated increase of skeletal muscle mass by promoting insulin growth factor-I production and mitochondrial biogenesis. Moreover, losartan decreased the intramuscular expression of transcription factor EB (TFEB), a transcriptional inducer of E3 ubiquitin ligase regulated by AT-II. In vitro assays illustrated that losartan promoted mitochondrial biogenesis and reduced TFEB expression in AT-II-stimulated rat myocytes, thereby potentiating the inhibitory effects of BCAAs on the UPS and caspase-3 cleavage. CONCLUSION:
|
Authors | Soichi Takeda, Kosuke Kaji, Norihisa Nishimura, Masahide Enomoto, Yuki Fujimoto, Koji Murata, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji |
Journal | Molecular nutrition & food research
(Mol Nutr Food Res)
Vol. 65
Issue 24
Pg. e2100526
(12 2021)
ISSN: 1613-4133 [Electronic] Germany |
PMID | 34687151
(Publication Type: Journal Article)
|
Copyright | © 2021 Wiley-VCH GmbH. |
Chemical References |
- Amino Acids, Branched-Chain
- Angiotensin Receptor Antagonists
|
Topics |
- Amino Acids, Branched-Chain
(metabolism)
- Angiotensin Receptor Antagonists
(metabolism, pharmacology)
- Animals
- Humans
- Liver Cirrhosis
(drug therapy, pathology)
- Muscle, Skeletal
(metabolism)
- Muscular Atrophy
(drug therapy, etiology, prevention & control)
- Rats
- Rats, Inbred F344
|